$LXRX Update + News

Hi all,

https://www.globenewswire.com/news-release/2025/02/18/3027794/0/en/Published-Data-in-The-Lancet-Diabetes-Endocrinology-Highlights-Unique-Efficacy-Benefits-of-Sotagliflozin-to-Reduce-Major-Adverse-Cardiovascular-Events-MACE.html

This morning LXRX published a PR highlighting a study on their Sotafliglozin drug, which explained that the drug was over more effective than traditional mainstream drugs in dealing with cardiovascular health issues.

Negative FDA comments on SOTAFLIGLOZIN caused the SP to depreciate from 1.5 to a low of 0.66. This recent news update could reverse some of the depreciative effects of the FDA's comments and cause the SP to rise, ahead of the phase 2b topline data expected in the coming weeks.

The rise to 0.9 this morning could just be premarket noise, so we won't be getting excited until we see some more volume and even then hold out for the topline data...

Myself and skittles are holding out for this, as we expect it will be the primary catalyst.

If you are looking to enter always do your own DD and thorough risk evaluation.

PRICE CALLED: 0.65 CURRENT PRICE: 0.9